MAPK4

Chr 18

mitogen-activated protein kinase 4

Also known as: ERK-4, ERK4, PRKM4, p63-MAPK, p63MAPK

Mitogen-activated protein kinase 4 is an atypical MAP kinase that phosphorylates microtubule-associated protein 2 and forms regulatory complexes with MAPKAPK5, potentially promoting cell cycle entry. Mutations cause autosomal recessive intellectual disability with microcephaly, seizures, and spasticity. This gene is highly constrained against loss-of-function variants, suggesting intolerance to functional disruption.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
16
Pubs (1 yr)
43
P/LP submissions
0%
P/LP missense
0.52
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryMAPK4
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.25) despite low pLI — interpret in context.
📋
ClinVar Variants
41 unique Pathogenic / Likely Pathogenic· 89 VUS of 143 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.52LOEUF
pLI 0.219
Z-score 3.13
OE 0.25 (0.130.52)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
1.68Z-score
OE missense 0.76 (0.690.83)
282 obs / 373.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.25 (0.130.52)
00.351.4
Missense OE0.76 (0.690.83)
00.61.4
Synonymous OE0.99
01.21.6
LoF obs/exp: 5 / 20.2Missense obs/exp: 282 / 373.1Syn Z: 0.09
DN
0.6161th %ile
GOF
0.73top 25%
LOF
0.4135th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

143 submitted variants in ClinVar

Classification Summary

Pathogenic40
Likely Pathogenic1
VUS89
Likely Benign5
40
Pathogenic
1
Likely Pathogenic
89
VUS
5
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
40
0
40
Likely Pathogenic
0
0
1
0
1
VUS
0
85
4
0
89
Likely Benign
0
1
2
2
5
Benign
0
0
0
0
0
Total086472135

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

MAPK4 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →